|
|
Article: Neurocrine Biosciences Ramps Up Phase III Clinical Trials for NBI-34060 In Primary (Chronic) and Transient Insomnia; The Company Is on Track Initiating the Most Comprehensive Clinical Program in Insomnia.
- Article from:
- PR Newswire
- Article date:
- March 19, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- Neurocrine Biosciences, Inc. announced today that it is initiating three additional pivotal Phase III clinical trials of NBI-34060 Immediate Release (IR) in over 1200 patients. The Company's first Phase III study with NBI-34060-IR was previously initiated in 500 patients in late 2001. With this announcement the Company will currently be conducting four of eight planned Phase III clinical trials with NBI-34060. According to the clinical program accepted by the Food and Drug Administration (FDA) at the Company's end of Phase II meeting, Neurocrine plans to conduct a total of five Phase III clinical trials with NBI-34060-IR and three Phase III trials with ...